Capricor Therapeutics (NASDAQ:CAPR) Trading Down 4.7% – What’s Next?

Capricor Therapeutics Inc (NASDAQ:CAPR) was down 4.7% during mid-day trading on Thursday . The stock traded as low as $12.91 and last traded at $12.56. Approximately 519,153 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 1,387,494 shares. The stock had previously closed at $13.18.

Analyst Ratings Changes

CAPR has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, Capricor Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Trading Down 2.6 %

The stock has a market capitalization of $522.91 million, a P/E ratio of -10.85 and a beta of 4.10. The business has a fifty day simple moving average of $14.00 and a 200 day simple moving average of $14.84.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15. The firm had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. As a group, research analysts forecast that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors have recently bought and sold shares of the company. Magnus Financial Group LLC bought a new position in shares of Capricor Therapeutics during the 4th quarter worth $276,000. State Street Corp lifted its holdings in Capricor Therapeutics by 27.8% during the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after purchasing an additional 111,291 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Capricor Therapeutics by 419.5% in the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock valued at $855,000 after purchasing an additional 45,381 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at approximately $3,806,000. Finally, Black Diamond Financial LLC bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $3,833,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.